BLOG / 🇮🇳 India / index intelligence · · daily

BSE Sensex 30 Stocks Regulatory Filings — October 13, 2026

India BSE SENSEX 30

By Gunpowder Editorial ·

1 high priority 10 medium priority 11 total filings analysed

Executive Summary

Across the 11 filings for the BSE SENSEX 30 stream dated 2026-10-13, the dominant theme is a calendar-heavy session: four SENSEX 30 constituents (HDFC Bank, Eternal, Larsen & Toubro, Bajaj Finance) flagged upcoming results or earnings calls in the Oct 17 to Oct 27 window, so the near-term catalyst path is results-driven rather than news-driven.

The most material development is Sun Pharmaceutical's mixed disclosure: a proposed ~$11.75 billion Organon acquisition funded by $9.5-10.0 billion of new debt, with CRISIL and ICRA affirming AAA/Stable, against Q1 FY27 operating income up ~10% YoY to Rs 15,300 Crore but US formulations down 10% and operating margin easing to 29% from 31.1%. Bharat Electronics reported Rs.533 Crore of fresh orders since 17 September 2026, a positive order-inflow signal in defence. InterGlobe Aviation (IndiGo) disclosed a customs duty demand of INR 3.5 crore that management says is immaterial and will contest. Insider and capital-allocation data are largely absent from this batch, so conviction and shareholder-return signals are limited. The Adani Ports disclosure lacks transaction detail and cannot be classified. Overall the batch is low-materiality apart from Sun Pharma, with no period-over-period financial figures disclosed in most filings.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: Corporate governance · Board meeting · Company update · Insider trading

Tracking the trend? Catch up on the prior BSE Sensex 30 Stocks Regulatory Filings digest from October 05, 2026.

Investment Signals (9)

  • Q1 FY27 operating income up ~10% YoY to Rs 15,300 Crore and India formulations up 16%, but US formulations down 10% and operating margin at 29% vs 31.1% prior; leverage to rise to 1.5-2.0x net debt/EBITDA in FY2028 on the Organon deal

  • Pro-forma combined revenue of ~$12.4 billion with EBITDA margin guided at 28-30% post-Organon, signalling scale benefits offset by integration leverage

  • Fresh orders of Rs.533 Crore since 17 September 2026 across communication, avionics, cyber security, drones and jammers, reinforcing defence order momentum

  • Rating agencies affirmed AAA/Stable (CRISIL on a proposed Rs.15000 Crore NCD programme; ICRA on NCDs), indicating the balance sheet remains strong despite the acquisition debt

  • HDFC Bank ↓ (NEUTRAL)
    ▲

    Q2 and H1 FY27 results call on Saturday, 17 October 2026 at 16:00 IST; the filing discloses no financial figures, so no period-over-period signal can yet be drawn

  • ▲

    Q2 FY27 results call on Monday, 19 October 2026 at 18:00 IST hosted by Vice Chairman & MD Rajeev Jain and CFO Sandeep Jain; no figures disclosed

  • Infosys ↓ (BULLISH)
    ▲

    Infosys Springboard has enabled more than 2.5 lakh job offers, halfway to its 5 lakh target by 2030, a positive CSR/brand signal with no direct P&L impact

  • InterGlobe Aviation (IndiGo) (NEUTRAL)
    ▲

    Customs duty demand of INR 3,50,00,000 on ATF imports (May 2024 to August 2025), management says no significant impact on financials or operations and will appeal

  • New York non-deal roadshow on 12 October 2026 relied on the Q1 FY27 presentation of 30 July 2026 with no unpublished price-sensitive information shared, a governance-clean investor-engagement signal

Risk Flags (7)

  • Organon deal requires $2.0-2.5 billion from cash and accruals plus $9.5-10.0 billion of new debt, including takeover of Organon's ~$8.5 billion existing debt; net debt/EBITDA to peak at 1.5-2.0x in FY2028

  • US formulations sales declined 10% YoY amid generics weakness and operating margin fell to 29% from 31.1%, eroding earnings quality just as the company takes on a large acquisition

  • Unresolved US FDA import alert on Halol (Dec 2022), warning letters for Dadra and Mohali, and OAI classification for Baska remain open, adding compliance risk to the combined entity

  • ▼

    Demand order from Principal Commissioner of Customs, Ahmedabad (received 12 October 2026) with interest, fine and penalty; the disclosure was delayed due to an internal communication lag, a governance point to monitor

  • Reg. 29(2) SAST filing dated 13 October 2026 with acquirer identity, holding change and share count not available in the supplied material; a possible promoter-group stake change of unknown size cannot be sized

  • Sector not specified and filing timeliness/completeness unverified, limiting any reliable classification of the transaction's direction

  • Pro-forma EBITDA margin of 28-30% sits below the current 29-31% standalone range in the best case, implying dilution risk if synergies lag

Opportunities (8)

  • Rs.533 Crore of incremental orders in one inter-disclosure window, across high-value categories such as cyber security, avionics and drones; a Navratna PSU with recurring order flow

  • India formulations grew 16% YoY in Q1 FY27, the strongest growth driver in the disclosure and a hedge against US generics weakness

  • Acquisition of Organon (~$12.4 billion pro-forma revenue) would materially scale the business; if synergies close the 28-30% margin gap, re-rating potential exists

  • AAA/Stable affirmations from two agencies signal that acquisition funding is not expected to threaten the rating, supporting cost of debt for the NCD programme

  • Results call on 19 October 2026 with senior management (CFO and MD) presenting; a near-term catalyst for lending-sector sentiment

  • ◆

    Results call on 17 October 2026 provides an early read on banking sector NIM and asset quality trends for SENSEX 30 weighting

  • ◆

    Board approval of results and 5:00 PM IST call on 21 October 2026 with transcript publication; a near-term sentiment event for the consumer-internet name

  • Program halfway to 5 lakh job offers by 2030 reinforces Infosys' ESG and CSR positioning, relevant for ESG-screened institutional flows

Sector Themes (5)

  • Pharma Scale vs Balance-Sheet Strain
    ◆

    Sun Pharma's Organon deal illustrates the sector theme of large cross-border acquisitions funded by debt, with leverage peaking at 1.5-2.0x net debt/EBITDA in FY2028 before deleveraging; the rating affirmations suggest the market accepts this tradeoff for scale [IMPLICATION: watch for other Indian pharma acquirers following the same template]

  • Domestic vs Export Divergence in Pharma
    ◆

    India formulations up 16% YoY versus US formulations down 10% YoY inside one company; the sector theme is domestic-market resilience offsetting US generic pricing pressure [IMPLICATION: favour domestic-weighted pharma exposure over US-generic-dependent names]

  • Defence Order Inflow Continuing
    ◆

    Bharat Electronics' Rs.533 Crore inflow across communication, avionics, cyber and drone categories fits a sustained defence procurement cycle [IMPLICATION: order visibility supports multi-quarter revenue guidance in defence PSUs]

  • Results-Season Clustering
    ◆

    Four SENSEX 30 constituents (HDFC Bank, Bajaj Finance, Eternal, Larsen & Toubro) announced Q2 FY27 results/calls for 17-27 October 2026, with most filings withholding financial figures; the theme is that near-term price discovery will come from the calls rather than the intimations [IMPLICATION: position around the calendar rather than on the filings themselves]

  • Governance and Disclosure Hygiene
    ◆

    InterGlobe's delayed disclosure of a customs order and Adani Ports' incomplete SAST filing both point to disclosure-timeliness and completeness as a recurring theme [IMPLICATION: prioritise filings with clean, timely disclosure when comparing constituents]

Watch List (7)

Filing Analyses (11)
HDFC Bank Limited Analyst/Investor Meet neutral materiality 3/10

13-10-2026

HDFC Bank Limited has announced that it will host an earnings call with analysts and investors at 16:00 IST on Saturday, October 17, 2026, to discuss its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The call is a group meeting, with dial-in numbers, international toll-free access and pre-registration details provided, and an audio recording will be made available on the Bank's website later. The filing contains no financial figures or performance metrics.

  • · Earnings call scheduled for 16:00 IST on Saturday, October 17, 2026, following a board meeting intimation dated September 22, 2026
  • · Call is a group meeting; dial-in numbers in India and toll-free numbers for USA, Singapore, UK and Hong Kong are provided
  • · Pre-registration available via a third-party reservation link to avoid wait time
  • · Audio recording of the call to be posted on the Bank's website in due course
Sun Pharmaceutical Industries Limited Market Notice mixed materiality 8/10

13-10-2026

Sun Pharmaceutical Industries received fresh credit ratings from CRISIL and ICRA, with CRISIL assigning 'AAA/Stable' to a proposed Rs.15000 Crore NCD programme and reaffirming its existing ratings, and ICRA assigning '[ICRA]AAA (Stable)' to NCDs. The ratings factor in the proposed ~$11.75 billion acquisition of Organon & Co., which is expected to temporarily raise leverage (net debt/EBITDA of 1.5-2.0x in FY2028) before deleveraging. Operating performance is mixed: Q1 FY27 operating income rose ~10% YoY to Rs 15,300 Crore and India formulations grew 16%, but US formulations sales declined 10% amid generics weakness and operating margin moderated to 29% from 31.1%.

  • · Organon acquisition to be funded with $2.0-2.5 billion from cash surplus and internal accruals, and $9.5-10.0 billion of additional debt, including takeover of Organon's ~$8.5 billion existing debt
  • · Pro-forma combined revenue of ~$12.4 billion, with EBITDA margin expected at 28-30%
  • · US FDA import alert on Halol facility (Dec 2022), warning letters for Dadra and Mohali, and OAI classification for Baska remain unresolved regulatory risks
  • · Rating agencies expect the US tariff/MFN pricing environment and the two-year US administration agreement to be key monitorables
ETERNAL LIMITED Corporate Governance neutral materiality 4/10

13-10-2026

Eternal Limited (formerly Zomato Limited) has intimated that its board of directors will meet on Wednesday, October 21, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company will also host an earnings conference call on the same day at 5:00 PM IST to discuss the results, with pre-registration required and transcript and audio to be posted on its investor relations website.

  • · Board meeting scheduled for October 21, 2026, to approve unaudited results for the quarter and half year ended September 30, 2026
  • · Earnings conference call scheduled for October 21, 2026 at 5:00 PM IST, requiring pre-registration
  • · Transcript and audio recording to be published on the company's investor relations website
  • · Filing made under Regulation 29 of SEBI LODR Regulations, 2015; scrip code 543320, symbol ETERNAL
Larsen & Toubro Limited Board Meeting neutral materiality 3/10

13-10-2026

Larsen & Toubro Limited has notified stock exchanges that its Board of Directors will meet on Tuesday, 27 October 2026 to consider and approve the unaudited consolidated and standalone financial results for the quarter and half year ended 30 September 2026. The filing is a procedural intimation under SEBI LODR Regulations 29(1)(a) and 50(1) and contains no financial figures.

  • · Board meeting scheduled for Tuesday, 27 October 2026
  • · Results under consideration cover the quarter and half year ended 30 September 2026
  • · Filed under SEBI LODR Regulations 29(1)(a) and 50(1)
InterGlobe Aviation Limited Company Update neutral materiality 3/10

13-10-2026

InterGlobe Aviation Limited (IndiGo) disclosed under Regulation 30 that the Principal Commissioner of Customs, Ahmedabad, passed an order confirming a demand for additional customs duty on ATF imports for May 2024 to August 2025, along with interest, fine and penalty totaling INR 3,50,00,000. The company believes it correctly deposited the duty, will contest the order before the appropriate appellate authority, and states there is no significant impact on its financials or operations.

  • · Demand covers customs duty on ATF imports for the period May 2024 to August 2025, plus interest, fine and penalty.
  • · The disclosure was delayed due to an unintentional lag in internal communication of the order's details.
  • · Order was received on October 12, 2026 from the Office of the Principal Commissioner of Customs, Ahmedabad, Gujarat.
ETERNAL LIMITED Analyst/Investor Meet neutral materiality 4/10

13-10-2026

Eternal Limited (formerly Zomato Limited) has intimated that its Board of Directors will meet on Wednesday, October 21, 2026, to consider and approve the un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company will host an earnings conference call on the same day at 5:00 PM IST to discuss the results, with pre-registration required and the transcript and audio recording to be published on its investor relations website.

  • · Board meeting scheduled for Wednesday, October 21, 2026
  • · Earnings conference call scheduled for October 21, 2026 at 5:00 PM IST
  • · Participants must pre-register using the provided registration link; access details are sent by email after registration
  • · Call transcript and audio recording to be made available at eternal.com/investor-relations
  • · Intimation filed under SEBI (LODR) Regulation 29 and hosted on the company website
Adani Ports and Special Economic Zone Limited Insider Trading / Sast neutral materiality 3/10

13-10-2026

Adani Ports and Special Economic Zone Ltd (BSE: 532921) filed a disclosure under Reg. 29(2) of SEBI (SAST) Regulations, 2011 dated October 13, 2026. The filing summary provided contains only the title and headline; the underlying transaction details, acquirer/seller identities, share counts, holding percentages and values are NOT_DISCLOSED in the material supplied. Sentiment cannot be meaningfully assessed beyond routine-disclosure classification.

  • · Filing title identifies BSE scrip code 532921 and disclosure date of October 13, 2026
  • · Sector is not specified in the source data
  • · Full filing annexure (acquirer details, pre/post holding, share count, mode of acquisition) is required before any signal can be classified
Bajaj Finance Limited Analyst/Investor Meet neutral materiality 3/10

13-10-2026

Bajaj Finance Limited has intimated under Regulation 30 of the SEBI (LODR) Regulations, 2015 that a conference call with analysts and institutional investors will be held on Monday, 19 October 2026 at 6:00 p.m. IST to discuss financial results for the quarter ended 30 September 2026 (Q2 FY27). The call will be hosted by Vice Chairman & Managing Director Rajeev Jain and COO & CFO Sandeep Jain, along with the senior management team. The filing contains no financial figures, so no performance data is disclosed in this intimation.

  • · Conference call date: Monday, 19 October 2026, 6:00 p.m. IST (08:30 ET, 13:30 BST, 20:30 HKT/SGT)
  • · Pre-registration is required via a registration link; dial-in numbers and passcode are sent by email after registration
  • · Universal dial-in: +91 22 6280 1375 / +91 22 7115 8276; toll-free access available in USA, UK, Singapore and Hong Kong
  • · Filing was made to both BSE (Scrip Code 500034) and NSE (Symbol BAJFINANCE-EQ)
Infosys Limited Company Update positive materiality 2/10

13-10-2026

Infosys Foundation announced that its Infosys Springboard Livelihood Program has enabled more than 2.5 lakh job offers across India, reaching the halfway milestone toward its goal of 5 lakh (half a million) job opportunities by 2030. The program, launched last year, operates through 20 implementation partners and has generated over 1.17 lakh job offers for graduates, over 96,000 for undergraduates, over 1.25 lakh for women, and over 1,000 for persons with disabilities. This is a philanthropic/CSR disclosure with no direct financial impact on Infosys' results.

  • · Program partners include Magic Bus, Centum Foundation, Aga Khan Rural Support Programme (India), and ICT Academy
  • · Employment platform provided by AssisTech Foundation; Association of People with Disability to expand access for persons with disabilities
  • · Infosys Foundation was established in 1996 and supports education, healthcare, women empowerment, and environmental sustainability
Mahindra & Mahindra Limited Company Update neutral materiality 2/10

13-10-2026

Mahindra & Mahindra Ltd. disclosed under Regulation 30 of SEBI LODR that it participated in a Non-Deal Roadshow in New York on 12 October 2026, engaging with funds and investors. The company stated that its previously submitted Q1 FY27 analyst meet presentation (dated 30 July 2026) was used and that no unpublished price sensitive information was shared. The filing contains no financial results, revenue, or other quantitative performance data.

  • · The roadshow concluded at 6.00 p.m. EDT on 12 October 2026 (3:30 a.m. IST on 13 October 2026)
  • · The company referred only to publicly available documents during discussions
  • · The presentation was originally filed with exchanges on 30 July 2026 and is hosted on the company website
Bharat Electronics Limited Market Notice positive materiality 5/10

13-10-2026

Bharat Electronics Limited (BEL), a Navratna Defence PSU, disclosed under Regulation 30 of SEBI (LODR) Regulations, 2015 that it has secured additional orders worth Rs.533 Crore since its last order disclosure on 17 September 2026. Major order categories include communication equipment, avionics, cyber security solutions, drones, jammers, software solutions, upgrades, spares, and services.

  • · Order inflow is cumulative since the previous disclosure dated 17 September 2026
  • · Orders span defence electronics categories including communication, avionics, cyber security, drones and jammers

Get daily alerts with 9 investment signals, 7 risk alerts, 8 opportunities and full AI analysis of all 11 filings

₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: BSE Sensex 30 Stocks Regulatory Filings

🇮🇳 More from India

View all →